Bristol To Focus On Paraplatin For Oncology Growth; UFT Review Delayed

Bristol-Myers Squibb is looking to Paraplatin (carboplatin) to lead oncology growth in the wake of a court decision opening the door to generic competition for its Taxol (paclitaxel) franchise.